AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11105976 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Search Model (VSM)
Number of subjects: 0
Study 9362196 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 25
Study 9362196 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 25
Study 9362196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 25
Study 9362196 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 25
Study 9362196 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study 8217176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8217176 — intervention group
Group type: COMPARATOR
Intervention: 8 mg of ondansetron
Number of subjects: 30
Study 8217176 — intervention group
Group type: COMPARATOR
Intervention: 16 mg of ondansetron
Number of subjects: 30
Study 3318574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 35
Study 3318574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol combined with atropine sulfate
Number of subjects: 35
Study 3318574 — intervention group
Group type: COMPARATOR
Intervention: Inhaled atropine sulfate
Number of subjects: 35
Study 29861218 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape application
Number of subjects: 20
Study 29861218 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape with EMLA
Number of subjects: 20
Study 29861218 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 20
Study 29861218 — intervention group
Group type: COMPARATOR
Intervention: Sham tape application
Number of subjects: 20
Study 29861218 — intervention group
Group type: COMPARATOR
Intervention: Control without kinesiology tape or EMLA
Number of subjects: 20
Study 28215835 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopic treatment (ET) with prophylaxis until resolution
Number of subjects: 77
Study 28215835 — intervention group
Group type: COMPARATOR
Intervention: Continuous antibiotic prophylaxis (CAP)
Number of subjects: 77
Study 28215835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ET and CAP
Number of subjects: 77
Study 26200017 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST (maximal cadence before test)
Number of subjects: 28
Study 23980148 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-like auditory stimuli exposure
Number of subjects: 0
Study 23980148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal speech exposure
Number of subjects: 0
Study 23980148 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalization of learning effect
Number of subjects: 0
Study 21429706 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based constraint-induced therapy (CIT)
Number of subjects: 21
Study 21429706 — intervention group
Group type: COMPARATOR
Intervention: Dose-matched home-based control intervention
Number of subjects: 21
Study 18328855 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 22926
Study 16340722 — intervention group
Group type: EXPERIMENTAL
Intervention: Region-of-interest (ROI) template for Z-score images of 3-D stereotactic surface projections (3-D SSP)
Number of subjects: 25
Study 16340722 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of Z-score images
Number of subjects: 25
Study 14552104 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methadone (epPCA group)
Number of subjects: 30
Study 14552104 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methadone (ivPCA group)
Number of subjects: 30
Study 12706639 — intervention group
Group type: EXPERIMENTAL
Intervention: bemiparin (3500 IU, anti-Xa)
Number of subjects: 12
Study 12706639 — intervention group
Group type: COMPARATOR
Intervention: tinzaparin (4500 IU, anti-Xa)
Number of subjects: 12
Study 12706639 — intervention group
Group type: EXPERIMENTAL
Intervention: both formulations
Number of subjects: 12
Study 10494485 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (1 mg NET‐Ac and 20 micrograms EE daily)
Number of subjects: 60
Study 8945028 — intervention group
Group type: EXPERIMENTAL
Intervention: Autosensing feature activated
Number of subjects: 55
Study 8945028 — intervention group
Group type: EXPERIMENTAL
Intervention: Autosensing adjusted sensitivity
Number of subjects: 55
Study 8945028 — intervention group
Group type: COMPARATOR
Intervention: Autosensing compared to recommended 2:1 safety margin
Number of subjects: 55
Study 1994405 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 12
Study 1994405 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (US)
Number of subjects: 12
Study 1994405 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 12
Study 6400709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg before the evening meal
Number of subjects: 14
Study 6400709 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg
Number of subjects: 14
Study 3915888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg/day
Number of subjects: 30
Study 3915888 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 40 mg/day
Number of subjects: 30
Study 29735967 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Yanghe Decoction
Number of subjects: 80
Study 29735967 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib-sulfasalazine
Number of subjects: 80
Study 28735464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose protocol
Number of subjects: 50
Study 28735464 — intervention group
Group type: COMPARATOR
Intervention: High-dose protocol
Number of subjects: 50
Study 26495694 — intervention group
Group type: EXPERIMENTAL
Intervention: BCP/PLGA
Number of subjects: 24
Study 26495694 — intervention group
Group type: COMPARATOR
Intervention: P-TCP
Number of subjects: 24
Study 26495694 — intervention group
Group type: COMPARATOR
Intervention: DPBB
Number of subjects: 24
Study 24065010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glucose suspension group (automated insulin suspension)
Number of subjects: 95
Study 24065010 — intervention group
Group type: COMPARATOR
Intervention: Pump-only therapy (standard insulin pump)
Number of subjects: 95
Study 24065010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study 22117998 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg, daily, orally for 8 weeks
Number of subjects: 55
Study 22117998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18271772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji VII glass ionomer cement (GIC) applied to the cervical third of posterior teeth
Number of subjects: 100
Study 18271772 — intervention group
Group type: COMPARATOR
Intervention: Control side (no GIC applied)
Number of subjects: 100
Study 18271772 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention of GIC
Number of subjects: 100
Study 16510486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy use during the 9-day assessment period
Number of subjects: 38
Study 16510486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy use
Number of subjects: 38
Study 12633548 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril (4 mg daily) and indapamide (at physician's discretion)
Number of subjects: 6105
Study 12633548 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril and indapamide
Number of subjects: 6105
Study 12633548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 11808057 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine varnish treatment
Number of subjects: 236
Study 11808057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 11808057 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 236
Study 9209249 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg minoxidil
Number of subjects: 9
Study 9209249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg glyburide
Number of subjects: 9
Study 9209249 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg minoxidil with 2.5 mg glyburide
Number of subjects: 9
Study 9209249 — intervention group
Group type: COMPARATOR
Intervention: 5 mg glyburide
Number of subjects: 9
Study 9209249 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg glyburide with 5 mg minoxidil
Number of subjects: 9
Study 8417730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain‐Related Self Statements Scale (PRSS) - Catastrophizing
Number of subjects: 415
Study 8417730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain‐Related Self Statements Scale (PRSS) - Coping
Number of subjects: 415
Study 8417730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain‐Related Control Scale (PRCS) - Helplessness
Number of subjects: 415
Study 8417730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain‐Related Control Scale (PRCS) - Resourcefulness
Number of subjects: 415
Study 3744299 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam
Number of subjects: 22
Study 3744299 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 31096794 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling with topical bleomycin at 2 weeks interval
Number of subjects: 54
Study 31096794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 3 weeks interval
Number of subjects: 54
Study 31096794 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 54
Study 30101332 — intervention group
Group type: EXPERIMENTAL
Intervention: LCHP+ω‐3 diet
Number of subjects: 122
Study 30101332 — intervention group
Group type: EXPERIMENTAL
Intervention: LCHP diet
Number of subjects: 122
Study 30101332 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 diet
Number of subjects: 122
Study 30101332 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) diet
Number of subjects: 122
Study 27155210 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 194
Study 27155210 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic treatment)
Number of subjects: 194
Study 24008587 — intervention group
Group type: EXPERIMENTAL
Intervention: T. arjuna bark extract
Number of subjects: 60
Study 24008587 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 60
Study 21800222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask during CPAP
Number of subjects: 12
Study 21800222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal mask 1 during CPAP
Number of subjects: 12
Study 21800222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal mask 2 during CPAP
Number of subjects: 12
Study 21800222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask during auto-PAP
Number of subjects: 12
Study 21800222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal masks during auto-PAP
Number of subjects: 12
Study 21800222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask and oronasal masks during CPAP and auto-PAP
Number of subjects: 12
Study 19916063 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 11
Study 19916063 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (40 mg)
Number of subjects: 11
Study 19916063 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 11
Study 19916063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18462502 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 180
Study 18462502 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Substitution Therapy (NST)
Number of subjects: 180
Study 16626425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Cox-2 inhibitor prophylaxis of cystoid macular oedema
Number of subjects: 62
Study 16626425 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cataract surgery
Number of subjects: 62
Study 12880879 — intervention group
Group type: EXPERIMENTAL
Intervention: Noticing other teens smoking
Number of subjects: 6274
Study 12880879 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception that adults care about and disapprove of teen smoking
Number of subjects: 6274
Study 12880879 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived prevalence of smoking
Number of subjects: 6274
Study 11093486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 40
Study 11093486 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 9120451 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 27
Study 9120451 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day
Number of subjects: 27
Study 9120451 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 27
Study 9120451 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 27
Study 9120451 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (all doses)
Number of subjects: 27
Study 1490748 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 100
Study 1490748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 100
Study 3894129 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional insulin treatment or CSII (Continuous Subcutaneous Insulin Infusion)
Number of subjects: 70
Study 30203671 — intervention group
Group type: COMPARATOR
Intervention: Postoperative topical steroids alone (Group A)
Number of subjects: 100
Study 30203671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both steroidal and nonsteroidal anti‐inflammatory eye drops (Group B)
Number of subjects: 100
Study 30203671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study 28609362 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 562
Study 28609362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 28609362 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant octreotide treatment
Number of subjects: 562
Study 25265123 — intervention group
Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/platelet‐rich plasma (PRP)/collagen plug
Number of subjects: 41
Study 25265123 — intervention group
Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/recombinant human platelet‐derived growth factor BB (rhPDGF‐BB)/collagen plug
Number of subjects: 41
Study 25265123 — intervention group
Group type: COMPARATOR
Intervention: FDBA/β‐TCP/collagen plug
Number of subjects: 41
Study 23758998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for type 2 diabetes prevention
Number of subjects: 692
Study 23758998 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 692
Study 23758998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for dietary and exercise objectives
Number of subjects: 692
Study 23758998 — intervention group
Group type: COMPARATOR
Intervention: Usual care for dietary and exercise objectives
Number of subjects: 692
Study 23758998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for weight loss
Number of subjects: 692
Study 23758998 — intervention group
Group type: COMPARATOR
Intervention: Usual care for weight loss
Number of subjects: 692
Study 21385974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus stimulation at the P6 acupuncture point
Number of subjects: 264
Study 21385974 — intervention group
Group type: COMPARATOR
Intervention: ST stimulation over the ulnar nerve (control)
Number of subjects: 264
Study 18070144 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (300 mg)
Number of subjects: 42
Study 18070144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml of 0.9% sodium chloride)
Number of subjects: 42
Study 18070144 — intervention group
Group type: COMPARATOR
Intervention: Control (250 ml of 0.9% sodium chloride)
Number of subjects: 42
Study 16480969 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) in Group A
Number of subjects: 78
Study 16480969 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone in Group B
Number of subjects: 78
Study 16480969 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin vs Conventional therapy alone
Number of subjects: 78
Study 12527456 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 86
Study 12527456 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2
Number of subjects: 86
Study 10729395 — intervention group
Group type: COMPARATOR
Intervention: R192 allele in CAD patients
Number of subjects: 431
Study 10729395 — intervention group
Group type: COMPARATOR
Intervention: R192 allele in ischemic stroke patients
Number of subjects: 431
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg)
Number of subjects: 12
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (40 mg)
Number of subjects: 12
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg) with Fenfluramine (40 mg)
Number of subjects: 12
Study 8924191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (10 mg)
Number of subjects: 12
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (20 mg)
Number of subjects: 12
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (80 mg)
Number of subjects: 12
Study 8924191 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg) with Fenfluramine (80 mg)
Number of subjects: 12
Study 1546398 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with Hemoccult‐II
Number of subjects: 61938
Study 1546398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not screened)
Number of subjects: 61938
Study 3840743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation N (higher plasma fenofibrate level)
Number of subjects: 11
Study 3840743 — intervention group
Group type: COMPARATOR
Intervention: Formulation R (lower plasma fenofibrate level)
Number of subjects: 11
Study 3840743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 11
Study 29955889 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training (Technology)
Number of subjects: 375
Study 29955889 — intervention group
Group type: COMPARATOR
Intervention: In-person training (Traditional)
Number of subjects: 375
Study 29955889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training methods
Number of subjects: 375
Study 29906264 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX II score
Number of subjects: 831
Study 29906264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 831
Study 26908701 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL)
Number of subjects: 34
Study 26908701 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngoscope (CL)
Number of subjects: 34
Study 26908701 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL) to Classic laryngoscope (CL)
Number of subjects: 34
Study 24377403 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapies (Cognitive Behavioral Therapy and Psychoanalytic Therapy)
Number of subjects: 0
Study 24377403 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study (IMPACT-My Experience)
Number of subjects: 0
Study 24377403 — intervention group
Group type: COMPARATOR
Intervention: Randomized Controlled Trial (RCT)
Number of subjects: 0
Study 22094261 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive morphine analgesia (maximum of 14 days)
Number of subjects: 19
Study 22094261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20677963 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic oral appliance (orthodontic OA)
Number of subjects: 30
Study 20677963 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic oral appliance (OA)
Number of subjects: 30
Study 17242760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingerprint recognition technology for participant identification
Number of subjects: 0
Study 15100699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 325 mg
Number of subjects: 12
Study 15100699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15100699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12
Study 12387693 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (specific type not mentioned)
Number of subjects: 0
Study 12387693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional touch (participants touched on the wrist to have their pulse taken)
Number of subjects: 125
Study 10234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Social touch (unexplained touch to the same area of the arm)
Number of subjects: 125
Study 10234420 — intervention group
Group type: COMPARATOR
Intervention: No-touch control (participants told their pulse was being taken automatically without being touched)
Number of subjects: 125
Study 10234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Social touch with female experimenters
Number of subjects: 125
Study 10234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Social touch with women being touched by men
Number of subjects: 125
Study 9203950 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser induced shock wave lithotripsy (LISL)
Number of subjects: 34
Study 9203950 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 34
Study 9203950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined LISL and additional fragmentation techniques
Number of subjects: 34
Study 2008942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (175 mg)
Number of subjects: 48
Study 2008942 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (175 mg)
Number of subjects: 48
Study 7261830 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation of the head of the bed
Number of subjects: 55